Parkinson Disease Comprehensive NGS Panel

Panel Description

Overview:

The Parkinson Disease Comprehensive Panel examines 26 genes associated with an increased risk of developing the neurodegenerative condition: Parkinson Disease.

Who is this test for?

Patients with a personal and/or family history of Parkinson’s disease. Parkinson Disease is characterized by progressive movement and balance issues. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. Warning signs include, but are not limited to involuntary shaking of the hands, legs, jaw or tongue (tremors), slow movement (bradykinesia), stiff limbs (rigidity), or gait (walking) and balance problems.

What are the potential benefits for my patient?

Patients identified with a disease-causing change (a pathogenic or likely pathogenic variant) in a gene on this panel have an increased risk of developing the associated neurodegenerative disease. Genetic testing may be beneficial in the planning and decision-making process for treatment, psychosocial counseling, research study enrollment, and support programs for caregivers and patients. Your patient’s family members can also be tested to help define their risk. If a pathogenic variant is identified in your patient, close relatives (children, siblings, and parents) are up to 50% more likely to also be at increased risk.

Test Description

Order Options:

Sequencing
Del/Dup
Rush / STAT
Exclude VUS
Duo/Trio

Turnaround Time:

3-5 weeks

Cost:

Call for details

Genes:

ATP13A2, ATP1A3, CSF1R, DCTN1, DNAJC6, EIF4G1, FBXO7, GBA, GCH1, HTRA2, LRRK2, MAPT, NOTCH3, PARK7, PINK1, PLA2G6, POLG, PRKN, PRKRA, PRNP, SLC6A3, SNCA, TAF1, TH, UCHL1, VPS35 ( 26 genes )

Coverage:

96% at 20x

Specimen Requirements:

Blood (two 4ml EDTA tubes, lavender top) or Extracted DNA (3ug in EB buffer) or Buccal Swab or Saliva (kits available upon request)

Test Limitations:

All sequencing technologies have limitations. This analysis is performed by Next Generation Sequencing (NGS) and is designed to examine coding regions and splicing junctions. Although next generation sequencing technologies and our bioinformatics analysis significantly reduce the contribution of pseudogene sequences or other highly-homologous sequences, these may still occasionally interfere with the technical ability of the assay to identify pathogenic variant alleles in both sequencing and deletion/duplication analyses. Sanger sequencing is used to confirm variants with low quality scores and to meet coverage standards. If ordered, deletion/duplication analysis can identify alterations of genomic regions which include one whole gene (buccal swab specimens and whole blood specimens) and are two or more contiguous exons in size (whole blood specimens only); single exon deletions or duplications may occasionally be identified, but are not routinely detected by this test. Identified putative deletions or duplications are confirmed by an orthogonal method (qPCR or MLPA). This assay will not detect certain types of genomic alterations which may cause disease such as, but not limited to, translocations or inversions, repeat expansions (eg. trinucleotides or hexanucleotides), alterations in most regulatory regions (promoter regions) or deep intronic regions (greater than 20bp from an exon). This assay is not designed or validated for the detection of somatic mosaicism or somatic mutations.

CPT Codes:

CPT Code

81405, 81408, 81479

NOTE: The CPT codes listed on the website are in accordance with Current Procedural Terminology, a publication of the American Medical Association. CPT codes are provided here for the convenience of our clients. Clients who bill for services should make the final decision on which codes to use.